<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03301038</url>
  </required_header>
  <id_info>
    <org_study_id>16-013429</org_study_id>
    <secondary_id>R01DK112955</secondary_id>
    <nct_id>NCT03301038</nct_id>
  </id_info>
  <brief_title>Rifampin in CYP24A1-related Hypercalcemia and Hypercalciuria</brief_title>
  <acronym>RICHH</acronym>
  <official_title>Rifampin to Reduce Elevated Levels of Blood and Urine Calcium in Patients With Inactivating Mutations in the CYP24A1 Gene</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Hospital of Philadelphia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Children's Hospital of Philadelphia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the efficacy of rifampin in the treatment of hypercalcemia and/or
      hypercalciuria in participants with biallelic inactivating mutations of the CYP24A1 gene.
      Eligible subjects will receive rifampin for a total of 16 weeks during this study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Idiopathic infantile hypercalcemia (IIH; omim 143880) is a genetic disorder of mineral
      metabolism characterized by severe hypercalcemia and/or hypercalciuria, suppressed serum
      levels of parathyroid hormone (PTH) and elevated levels of the active vitamin D metabolite,
      1,25(OH)2D. Biallelic inactivating mutations of CYP24A1, the gene encoding the 24-hydroxylase
      enzyme that represents the principal pathway for inactivation of vitamin D metabolites, cause
      the most common and severe form of IIH.

      Investigators have preliminary data supporting a novel therapeutic approach to repurpose
      rifampin as an agent to induce over-expression of CYP3A4, an enzyme that is expressed in the
      liver and intestine. When CYP3A4 is induced, the increased enzyme activity provides an
      alternative catabolic pathway for inactivation of vitamin D metabolites. The purpose of this
      study is to obtain support for an open label, escalating dose study to assess the effect,
      safety, and tolerability of once daily oral rifampin in participants with IIH due to
      inactivating mutations in CYP24A1.

      In this study, Investigators will recruit 18 patients with biallelic inactivating mutations
      of CYP24A1. Participants will be observed for 8-weeks before a 16-week treatment phase of
      rifampin and 8 further weeks of observation. In addition to following the effect of treatment
      on calcium homeostasis, Investigators will also study the pharmacokinetics of rifampin in
      this condition and the effect on intestinal calcium absorption.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 2018</start_date>
  <completion_date type="Anticipated">December 2030</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum albumin-adjusted calcium</measure>
    <time_frame>up to 32 weeks</time_frame>
    <description>Measured at baseline and every 4 weeks</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum parathyroid hormone</measure>
    <time_frame>up to 32 weeks</time_frame>
    <description>Measured at baseline and every 4 weeks</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Urinary calcium excretion</measure>
    <time_frame>up to 32 weeks</time_frame>
    <description>Measured at baseline and every 4 weeks</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Intestinal calcium absorption</measure>
    <time_frame>8, 16 and 24 weeks post-dose</time_frame>
    <description>Measured using stable calcium isotopes three times during the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nephrocalcinosis</measure>
    <time_frame>Baseline and week 32</time_frame>
    <description>Renal ultrasound performed before and after treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rifampin pharmacokinetics</measure>
    <time_frame>8, 16 and 24 weeks post-dose</time_frame>
    <description>Measured three times during the study</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Idiopathic Infantile Hypercalcaemia - Severe Form</condition>
  <condition>Genetic Disease</condition>
  <condition>Hypercalcemia, Idiopathic, of Infancy</condition>
  <condition>Hypercalciuric Hypercalcemia</condition>
  <condition>Idiopathic Infantile Hypercalcemia - Mild Form</condition>
  <condition>Hypercalciuria</condition>
  <arm_group>
    <arm_group_label>All Subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rifampin</intervention_name>
    <description>Rifampin 5 mg/kg (max 300 mg) daily for 8 weeks, followed by rifampin 10 mg/kg (max 600 mg) daily for 8 weeks.</description>
    <arm_group_label>All Subjects</arm_group_label>
    <other_name>Rifadin</other_name>
    <other_name>Rifampicin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males or females age 6 months to 50 years.

          -  Biallelic mutations of CYP24A1

          -  Serum and/or urinary calcium above the normal reference range for age

          -  Serum PTH concentration &lt;20 pg/ml

          -  Elevated or normal serum concentration of 1,25-dihydroxyvitamin D3.

        Exclusion Criteria:

          -  Parents/guardians or subjects who, in the opinion of the Investigator, may be
             non-compliant with study schedules or procedures.

          -  Allergy to rifampin or related medications

          -  Current therapies with medications or foods that are considered by the research team
             to potentially affect mineral metabolism, alter clearance of rifampin, or inhibit
             CYP3A4.

          -  Pregnancy or breastfeeding

          -  Laboratory abnormalities that indicate clinically significant hepatic, or renal
             disease:

        AST/SGOT &gt; 2.0 times the upper limit of normal ALT/SGPT &gt; 2.0 times the upper limit of
        normal Total bilirubin &gt; 2.0 times the upper limit of normal Creatinine &gt; 2.0 times the
        upper limit of normal
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael A Levine, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children'sHospital of Philadelphia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michael A Levine, MD</last_name>
    <phone>267-426-3907</phone>
    <email>levinem@chop.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Colin P Hawkes, MD</last_name>
    <phone>215-590-3174</phone>
    <email>hawkesc@email.chop.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michael A Levine, MD</last_name>
      <phone>267-426-3907</phone>
      <email>levinem@chop.edu</email>
    </contact>
    <contact_backup>
      <last_name>Colin P Hawkes, MD</last_name>
      <phone>215-590-3174</phone>
      <email>hawkesc@email.chop.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Colin P Hawkes, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michael A Levine, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Hawkes CP, Li D, Hakonarson H, Meyers KE, Thummel KE, Levine MA. CYP3A4 Induction by Rifampin: An Alternative Pathway for Vitamin D Inactivation in Patients With CYP24A1 Mutations. J Clin Endocrinol Metab. 2017 May 1;102(5):1440-1446. doi: 10.1210/jc.2016-4048.</citation>
    <PMID>28324001</PMID>
  </reference>
  <reference>
    <citation>Dauber A, Nguyen TT, Sochett E, Cole DE, Horst R, Abrams SA, Carpenter TO, Hirschhorn JN. Genetic defect in CYP24A1, the vitamin D 24-hydroxylase gene, in a patient with severe infantile hypercalcemia. J Clin Endocrinol Metab. 2012 Feb;97(2):E268-74. doi: 10.1210/jc.2011-1972. Epub 2011 Nov 23.</citation>
    <PMID>22112808</PMID>
  </reference>
  <reference>
    <citation>Schlingmann KP, Kaufmann M, Weber S, Irwin A, Goos C, John U, Misselwitz J, Klaus G, Kuwertz-Bröking E, Fehrenbach H, Wingen AM, Güran T, Hoenderop JG, Bindels RJ, Prosser DE, Jones G, Konrad M. Mutations in CYP24A1 and idiopathic infantile hypercalcemia. N Engl J Med. 2011 Aug 4;365(5):410-21. doi: 10.1056/NEJMoa1103864. Epub 2011 Jun 15.</citation>
    <PMID>21675912</PMID>
  </reference>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 1, 2017</study_first_submitted>
  <study_first_submitted_qc>September 29, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 4, 2017</study_first_posted>
  <last_update_submitted>May 3, 2018</last_update_submitted>
  <last_update_submitted_qc>May 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 4, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>hypercalcemia</keyword>
  <keyword>nephrocalcinosis</keyword>
  <keyword>CYP24A1</keyword>
  <keyword>hypercalciuria</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Genetic Diseases, Inborn</mesh_term>
    <mesh_term>Hypercalcemia</mesh_term>
    <mesh_term>Hypercalciuria</mesh_term>
    <mesh_term>Infant, Newborn, Diseases</mesh_term>
    <mesh_term>Metabolism, Inborn Errors</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rifampin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

